Author

K-W Peng

Observed name: KW Peng

Observed institution: Mayo Clinic

OpenAlex ID: A5091844550

Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma

2017 · A Dispenzieri, C Tong, et al. · Leukemia · 154

Preclinical Pharmacology and Toxicology of Intravenous MV-NIS, an Oncolytic Measles Virus Administered With or Without Cyclophosphamide

2007 · R M Myers, S M Greiner, et al. · Clinical Pharmacology & Therapeutics · 126

Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies

2006 · H T Ong, K Hasegawa, et al. · Gene Therapy · 124

Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy

2010 · H Li, K-W Peng, et al. · Cancer Gene Therapy · 120

PDF

Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses

2012 · K-W Peng, R Myers, et al. · Gene Therapy · 96

PDF

Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors

2001 · K-W Peng, L Pham, et al. · Gene Therapy · 86

Curative one-shot systemic virotherapy in murine myeloma

2012 · S Naik, R Nace, et al. · Leukemia · 85

Dynamics of multiple myeloma tumor therapy with a recombinant measles virus

2009 · D Dingli, C Offord, et al. · Cancer Gene Therapy · 69

Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors

2013 · D Escobar-Zarate, Y-P Liu, et al. · Cancer Gene Therapy · 67

Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors

1999 · K-W Peng, R G Vile, et al. · Gene Therapy · 66

Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model

2006 · K-W Peng, E M Hadac, et al. · Cancer Gene Therapy · 59

Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus

2004 · A Kanerva, K R Zinn, et al. · Gene Therapy · 58

Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor

2004 · K-W Peng, P D Holler, et al. · Gene Therapy · 35

Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus

2011 · Y-P Liu, C Tong, et al. · Cancer Gene Therapy · 29

The innovative evolution of cancer gene and cellular therapies

2013 · P Lam, G Khan, et al. · Cancer Gene Therapy · 27

PDF

Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV

2013 · D N Yarde, S Naik, et al. · Cancer Gene Therapy · 14

PDF

Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease–substrate interaction

2003 · K J Johnson, K-W Peng, et al. · Gene Therapy · 14

Oral contrast enhances the resolution of in-life NIS reporter gene imaging

2013 · L Suksanpaisan, L Pham, et al. · Cancer Gene Therapy · 12

Abstract P6-21-03: Phase I trial of intratumoral (IT) administration of a NIS-expressing derivative manufactured from a genetically engineered strain of measles virus (MV)

2019 · MC Liu, K-W Peng, et al. · Cancer Research · 6

Early findings from a comparative oncology study evaluating systemic VSV therapy in client-owned dogs with spontaneous hematologic malignancies

2014 · Shruthi Naik, Alyssa Leblanc, et al. · Human Gene Therapy · 1

B590 Myeloma Cells as Measles Virus Delivery Vehicles

2009 · SJ Russell, C Liu, et al. · Clinical Lymphoma & Myeloma

A584 Preliminary Results of a Phase I Trial of Intravenous MV-NIS for Relapsed/Refractory Multiple Myeloma

2009 · C Tong, SJ Russell, et al. · Clinical Lymphoma & Myeloma

Sindbis vectors: illuminating the path to ovarian cancer therapy

2004 · K-W Peng, E Galanis · Gene Therapy

PDF

Works count: 23

Citation count: 1,247

H-index: 15

I10-index: 18